Associated Papers
Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.
Widjaja AO et al.
International Journal of Cancer, 2026
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
Jansche R et al.
Cell Death & Disease, 2026
Restoring Function to a Variant of p53 in Solid Tumors.
Lu X
The New England Journal of Medicine, 2026
Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.
Jani CT et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Integrative Computational Analysis of TP53 Exon 5-6 Mutations in Oral Cavity, Prostate, and Breast Cancers in a Senegalese Population.
Mbaye M et al.
Genes, 2026
Loss of p53 Provokes NF-κB-Dependent Disruption of Nucleolar Cap and Nucleoplasmic Redistribution of Fibrillarin During Nucleolar Stress.
Torii T et al.
Biomolecules, 2026
Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer.
Maleknia S et al.
Molecular Biomedicine, 2026
Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease.
Hsia B et al.
Life (basel, Switzerland), 2026
Actionable genomic landscape of biliary tract cancer in the Indian population.
Limaye S et al.
The Oncologist, 2026
Cell-free DNA from cerebrospinal fluid cytology specimens as a novel liquid biopsy approach for pediatric patients with primary central nervous system tumors.
Chun N et al.
Acta Neuropathologica Communications, 2026
Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.
Kasahara Y et al.
Familial Cancer, 2026
Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.
Yuen LD et al.
Haematologica, 2026
Mutant p53 disrupts antioxidant defense in fallopian tube epithelium via GSTAs suppression: A pathway to serous tubal carcinogenesis.
Burnett DB et al.
Free Radical Biology & Medicine, 2026
Correlation between P53 immunohistochemical staining and TP53 molecular testing in endometrial carcinomas: a detailed assessment of discrepant cases with implications for patient management.
Machuca-Aguado J et al.
Histopathology, 2026
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer.
Ye Y et al.
Cancer Science, 2026
Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Tao K et al.
Cancer Science, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Linking p53 rs1042522 Variant to Thyroid Cancer Risk: Insights from a Comprehensive Meta-Analysis of 2116 Cases.
Vakili-Ojarood M et al.
Cancer Investigation, 2026
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
Fedenko A et al.
Leukemia, 2026
Clinical Significance of Molecular Genetic Analysis in Diffuse Intrinsic Pontine Glioma: Two Case Reports.
Inamine I et al.
Pediatric Blood & Cancer, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.
Zhang H et al.
Annals of Hematology, 2026
Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors.
Xu X et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer.
Prasad M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
AI-Guided Conformational Dynamics of p53 L1 Loop Reveal an Allosteric Switch Regulating DNA Binding and Cancer Hotspots.
Navarro Acero P et al.
Journal of Chemical Information and Modeling, 2026
Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study.
Kang B et al.
International Journal of Molecular Sciences, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.
Singh S et al.
Cell Death and Differentiation, 2026
CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment.
Liu Y et al.
Colloids and Surfaces. B, Biointerfaces, 2026
Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.
Yang Y et al.
Human Pathology, 2026
Clonal Profiles in a Li-Fraumeni Syndrome Patient With SHH Medulloblastoma: Clonal Evolution, Genomics, and Clinical Implications.
Ramirez-Corona JA et al.
Pediatric Blood & Cancer, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer.
Zhao W et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo.
He C et al.
Angewandte Chemie (international Ed. in English), 2026
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.
DiNapoli SR et al.
The Journal of Clinical Investigation, 2026
T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.
Shen L et al.
The Journal of Clinical Investigation, 2026
Ultra-deep duplex sequencing reveals unique features of somatic evolution in the normal tissues of a family with Li-Fraumeni syndrome.
Colegrove HL et al.
Biorxiv : the Preprint Server for Biology, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Fece de la Cruz F et al.
Cancer Discovery, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026